Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study

Inclusion Criteria: * Male or female patients aged ≥40 years * Diagnosis of COPD with a ratio of post-bronchodilator (salbutamol 400 μg) forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) of less than 0.7 * Physicians' decision to start a first prescription fixed triple therapy with BDP/FF/GB NEXThaler® 88/5/9 in accordance with the marketing authorization * COPD Assessment Test (CAT) total score of at least 10 at the day of inclusion * Informed consent to participate in the study Exclusion Criteria: * Asthmatic patients * Patients with moderate or severe exacerbations within the 4 weeks prior to enrolment * Patients treated with fixed triple therapies within 6 months prior inclusion * Patients receiving pulmonary rehabilitation within 3 months prior to inclusion or within 6 months after inclusion * Concomitant participation in experimental clinical studies/investigations or participation in experimental clinical studies/investigations within 3 months prior to enrolment into the present study